A double‐blind study on ulotaront's impact on weight‐related parameters in schizophrenia patients with metabolic syndrome and prediabetes: Part II

Documenti analoghi

• An open‐label study on ulotaront's effects on insulin‐glucose regulation in schizophrenia patients with metabolic syndrome and prediabetes: Part I
  di: Snezana Milanovic, et al.
  Pubblicazione: (2025)
• The interaction of vitamin D supplementation with Omentin‐1 gene polymorphism on metabolic biomarkers, omentin‐1 levels and anthropometric measures in women with prediabetes: A double‐blind randomized controlled trial
  di: Roghayeh Molani‐Gol, et al.
  Pubblicazione: (2025)
• Evaluation of OCT2‐mediated drug–drug interactions between ulotaront and metformin in subjects with schizophrenia
  di: Guangqing Xiao, et al.
  Pubblicazione: (2024)
• Efficacy and safety of CT ‐868, a novel, fully biased, dual glucagon‐like peptide‐1/glucose‐dependent insulinotropic polypeptide receptor agonist, in type 2 diabetes: A double‐blind, randomized placebo controlled phase 2 trial
  di: Manu V. Chakravarthy, et al.
  Pubblicazione: (2025)
• Metformin use in prediabetes: A review of evidence and a focus on metabolic features among peri‐menopausal women
  di: Beth Shi Yu Lim, et al.
  Pubblicazione: (2025)